WO2005042018A3 - C-class oligonucleotide analogs with enhanced immunostimulatory potency - Google Patents
C-class oligonucleotide analogs with enhanced immunostimulatory potency Download PDFInfo
- Publication number
- WO2005042018A3 WO2005042018A3 PCT/US2004/036240 US2004036240W WO2005042018A3 WO 2005042018 A3 WO2005042018 A3 WO 2005042018A3 US 2004036240 W US2004036240 W US 2004036240W WO 2005042018 A3 WO2005042018 A3 WO 2005042018A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligonucleotide analogs
- oligonucleotides
- class oligonucleotide
- enhanced immunostimulatory
- immunostimulatory potency
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006538383A JP2007509983A (en) | 2003-10-30 | 2004-10-29 | C-class oligonucleotide analogs with enhanced immune stimulation |
BRPI0416079-7A BRPI0416079A (en) | 2003-10-30 | 2004-10-29 | c-class oligonucleotide analogs with increased immunostimulatory potency |
KR1020067008222A KR101107818B1 (en) | 2003-10-30 | 2004-10-29 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
AP2006003611A AP2006003611A0 (en) | 2003-10-30 | 2004-10-29 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
CA002540949A CA2540949A1 (en) | 2003-10-30 | 2004-10-29 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
AU2004285561A AU2004285561C1 (en) | 2003-10-30 | 2004-10-29 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
NZ546275A NZ546275A (en) | 2003-10-30 | 2004-10-29 | C-class oligonucleotides analogs with enhanced immunostimulatory potency |
EP04810173A EP1678303A2 (en) | 2003-10-30 | 2004-10-29 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
EA200600865A EA008741B1 (en) | 2003-10-30 | 2004-10-29 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
IL174428A IL174428A0 (en) | 2003-10-30 | 2006-03-20 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
AU2006201495A AU2006201495A1 (en) | 2003-10-30 | 2006-04-10 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
NO20061857A NO20061857L (en) | 2003-10-30 | 2006-04-26 | C-class oligonucleotide analogs with oct immunostimulatory potency |
IL175215A IL175215A0 (en) | 2003-10-30 | 2006-04-26 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
TNP2006000123A TNSN06123A1 (en) | 2003-10-30 | 2006-04-28 | C-class oligonucleotide analogs with enhaced immunostimulatory potency |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51619303P | 2003-10-30 | 2003-10-30 | |
US60/516,193 | 2003-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005042018A2 WO2005042018A2 (en) | 2005-05-12 |
WO2005042018A3 true WO2005042018A3 (en) | 2005-07-21 |
Family
ID=34549500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/036240 WO2005042018A2 (en) | 2003-10-30 | 2004-10-29 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
Country Status (23)
Country | Link |
---|---|
US (1) | US8188254B2 (en) |
EP (2) | EP1678303A2 (en) |
JP (1) | JP2007509983A (en) |
KR (1) | KR101107818B1 (en) |
CN (1) | CN101454451A (en) |
AP (1) | AP2006003611A0 (en) |
AU (2) | AU2004285561C1 (en) |
BR (1) | BRPI0416079A (en) |
CA (1) | CA2540949A1 (en) |
CR (1) | CR8423A (en) |
EA (1) | EA008741B1 (en) |
EC (1) | ECSP066589A (en) |
GE (1) | GEP20094767B (en) |
IL (2) | IL174428A0 (en) |
MA (1) | MA28182A1 (en) |
NO (1) | NO20061857L (en) |
NZ (2) | NZ546475A (en) |
OA (1) | OA13278A (en) |
SG (2) | SG122973A1 (en) |
TN (1) | TNSN06123A1 (en) |
UA (1) | UA88457C2 (en) |
WO (1) | WO2005042018A2 (en) |
ZA (2) | ZA200602352B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9328346B2 (en) | 2010-11-12 | 2016-05-03 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
US9382545B2 (en) | 2006-09-27 | 2016-07-05 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US9404126B2 (en) | 2006-06-12 | 2016-08-02 | Kuros Biosciences Ag | Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
DK1077722T3 (en) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Methods and products for the induction of mucosa immunity |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
DK2204186T3 (en) | 1999-02-17 | 2016-07-18 | Csl Ltd | Immunogenic complexes, and related methods |
WO2000061151A2 (en) * | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US6943240B2 (en) * | 2000-09-15 | 2005-09-13 | Coley Pharmaceuticals Gmbh | Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist |
DK2423335T3 (en) * | 2001-06-21 | 2014-08-18 | Dynavax Tech Corp | CHEMICAL IMMUNAL MODULATOR RELATIONS AND PROCEDURES FOR USE THEREOF |
CN1604795B (en) | 2001-08-17 | 2010-05-26 | 科勒制药股份公司 | Combination motif immune stimulatory oligonucleotides with improved activity |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
NZ573064A (en) | 2002-04-04 | 2011-02-25 | Coley Pharm Gmbh | Immunostimulatory G,U-containing oligoribonucleotides |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AR040996A1 (en) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
ATE544466T1 (en) * | 2002-10-29 | 2012-02-15 | Coley Pharm Group Inc | USE OF CPG OLIGONUCLEOTIDES TO TREAT HEPATITIS C VIRUS INFECTION |
WO2004053104A2 (en) * | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
EP1663316A2 (en) * | 2003-09-25 | 2006-06-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid lipophilic conjugates |
US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
CA2567789A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
CN102517292B (en) | 2005-11-25 | 2014-12-24 | 佐蒂斯比利时股份有限公司 | Immunostimulatory oligoribonucleotides |
EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
ES2526879T3 (en) * | 2006-02-15 | 2015-01-16 | Adiutide Pharmaceuticals Gmbh | Compositions and procedures for oligonucleotide formulations |
CN101622001A (en) * | 2007-01-26 | 2010-01-06 | Irm责任有限公司 | The purine compound and the compositions that are used for the treatment of plasmodium related diseases as inhibitors of kinases |
WO2008136748A1 (en) * | 2007-05-04 | 2008-11-13 | Index Pharmaceuticals Ab | Tumour growth inhibitory compounds and methods of their use |
WO2008138658A2 (en) * | 2007-05-14 | 2008-11-20 | Technische Universität München | Pharmaceutical compounds comprising abasic oligonucleotides |
ES2544484T3 (en) * | 2007-05-18 | 2015-08-31 | Adiutide Pharmaceuticals Gmbh | Phosphate modified oligonucleotide analogues with immunostimulatory activity |
EP2190440A1 (en) | 2007-08-13 | 2010-06-02 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
KR20100068422A (en) * | 2007-10-09 | 2010-06-23 | 콜리 파마슈티칼 게엠베하 | Immune stimulatory oligonucleotide analogs containing modified sugar moieties |
SI2176408T1 (en) * | 2008-01-31 | 2015-05-29 | Curevac Gmbh | NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS |
ES2616051T3 (en) | 2008-12-02 | 2017-06-09 | Wave Life Sciences Japan, Inc. | Method for the synthesis of modified nucleic acids in the phosphorus atom |
PT2376107E (en) * | 2008-12-09 | 2014-07-25 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
PT2411521E (en) | 2009-03-25 | 2015-04-21 | Univ Texas | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
DK2459231T3 (en) * | 2009-07-31 | 2016-09-05 | Ethris Gmbh | RNA with a combination of unmodified and modified nucleotides for protein expression |
CA2798323A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
JP5868324B2 (en) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | Asymmetric auxiliary group |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
SG10201700554VA (en) | 2011-07-19 | 2017-03-30 | Wave Life Sciences Pte Ltd | Methods for the synthesis of functionalized nucleic acids |
US20130028857A1 (en) | 2011-07-29 | 2013-01-31 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
JP6129844B2 (en) | 2011-09-14 | 2017-05-17 | ラナ セラピューティクス インコーポレイテッド | Multimeric oligonucleotide compounds |
CA2863084C (en) * | 2012-02-01 | 2020-07-07 | Gen-Probe Incorporated | Asymmetric hairpin target capture oligomers |
WO2013173645A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating utrn expression |
CN104583402A (en) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | Compositions and methods for modulating MECP2 expression |
SG11201407483YA (en) | 2012-05-16 | 2014-12-30 | Rana Therapeutics Inc | Compositions and methods for modulating smn gene family expression |
CN104583399A (en) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | Compositions and methods for modulating hemoglobin gene family expression |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
CA2873766A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating atp2a2 expression |
CA2878945A1 (en) | 2012-07-13 | 2014-01-16 | Wave Life Sciences Pte. Ltd. | Chiral control |
WO2014010718A1 (en) * | 2012-07-13 | 2014-01-16 | 株式会社新日本科学 | Chiral nucleic acid adjuvant |
AU2013288048A1 (en) | 2012-07-13 | 2015-01-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
CN103233011B (en) * | 2013-04-22 | 2014-11-05 | 中国科学技术大学 | Application of PEG (polyethylene glycol)-PLA (Poly Lactic Acid) nano-material-coated HBV (Hepatitis B Virus)-CpG (Cytosine Phosphate Guanosine) in prevention and/or treatment of hepatitis B |
AR095882A1 (en) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST |
WO2015024992A2 (en) * | 2013-08-22 | 2015-02-26 | Cytos Biotechnology Ag | Treatment of asthma |
CN105936906B (en) * | 2013-11-08 | 2019-06-21 | 上海交通大学 | Oligodeoxynucleotide molecule for the sequence units containing CpG being modified and application thereof |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
JPWO2015108048A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antitumor agent having antitumor activity |
WO2015108047A1 (en) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
KR20220106232A (en) | 2014-01-16 | 2022-07-28 | 웨이브 라이프 사이언시스 리미티드 | Chiral design |
GB2523187A (en) | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
TR201908550T4 (en) | 2014-06-04 | 2019-07-22 | Exicure Inc | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications. |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
EP3212824A4 (en) | 2014-10-30 | 2018-08-08 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
WO2016130943A1 (en) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
WO2016149455A2 (en) | 2015-03-17 | 2016-09-22 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
CN108697728A (en) | 2015-12-23 | 2018-10-23 | 昆士兰科技大学 | Nucleic acid oligomer and application thereof |
KR102617833B1 (en) | 2016-05-06 | 2023-12-27 | 엑시큐어 오퍼레이팅 컴퍼니 | Liposomal spherical nucleic acid (SNA) construct presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
WO2019066571A2 (en) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and uses thereof |
MX2020006243A (en) * | 2017-12-15 | 2020-09-03 | Bayer Animal Health Gmbh | Immunostimulatory oligonucleotides. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003015711A2 (en) * | 2001-08-17 | 2003-02-27 | Coley Pharmaceutical Group, Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
WO2004016805A2 (en) * | 2002-08-19 | 2004-02-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
WO2004039829A2 (en) * | 2002-10-29 | 2004-05-13 | Coley Pharmaceutical Group, Ltd. | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5194428A (en) * | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5004810A (en) * | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
NZ255028A (en) | 1992-07-02 | 1997-03-24 | Hybridon Inc | Antisense oligonucleotides resistant to nucleolytic degradation |
US5523389A (en) | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
US5646126A (en) | 1994-02-28 | 1997-07-08 | Epoch Pharmaceuticals | Sterol modified oligonucleotide duplexes having anticancer activity |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
US5696248A (en) | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0772619B2 (en) * | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
JP4111403B2 (en) * | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Immunostimulatory polynucleotide / immunomodulatory molecule complex |
WO1998029397A1 (en) | 1996-12-27 | 1998-07-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyrimidine compounds and medicinal use thereof |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
CA2281838A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
CA2301575C (en) * | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
US6221882B1 (en) * | 1997-07-03 | 2001-04-24 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
CA2323929C (en) | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
CA2328602A1 (en) | 1998-05-06 | 1999-11-11 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
EP1078053B1 (en) | 1998-05-14 | 2005-09-28 | Coley Pharmaceutical GmbH | METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
DK1077722T3 (en) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Methods and products for the induction of mucosa immunity |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
JP2002521489A (en) | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Stereoisomers of CpG oligonucleotides and related methods |
CA2341338A1 (en) | 1998-09-03 | 2000-03-16 | Coley Pharmaceutical Gmbh | G-motif oligonucleotides and uses thereof |
WO2000015645A1 (en) | 1998-09-11 | 2000-03-23 | Kyorin Pharmaceutical Co., Ltd. | Phosphonic ester derivatives and process for producing the same |
US6207819B1 (en) * | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
WO2000054803A2 (en) * | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
EP1177439B1 (en) | 1999-04-29 | 2004-09-08 | Coley Pharmaceutical GmbH | Screening for immunostimulatory dna functional modifiers |
WO2000076982A1 (en) | 1999-06-16 | 2000-12-21 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
DE60017259T2 (en) | 1999-08-13 | 2005-12-08 | Hybridon, Inc., Cambridge | Modulation of CPG oligonucleotide-mediated immune stimulation by positional modification of nucleosides |
EP1700603A3 (en) | 1999-09-25 | 2007-06-13 | Coley Pharmaceutical GmbH | Immunostimulatory nucleic acids |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
DE60131430T2 (en) * | 2000-01-14 | 2008-10-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | OLIGODE OXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE REACTION |
US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
CA2398432C (en) | 2000-01-26 | 2012-06-19 | Hybridon, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
CN1206259C (en) * | 2000-02-01 | 2005-06-15 | 新日铁化学株式会社 | Adhesive polyimide resin and adhesive laminate |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
IL151345A0 (en) | 2000-02-23 | 2003-04-10 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
US20040131628A1 (en) | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
CA2407942A1 (en) | 2000-05-01 | 2001-11-08 | Hybridon, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
US20020013287A1 (en) | 2000-05-09 | 2002-01-31 | Reliable Biopharmaceuticals, Inc. St Louis Missouri | Polymeric compounds useful as prodrugs |
DE60139689D1 (en) * | 2000-06-22 | 2009-10-08 | Univ Iowa Res Found | Combination of CpG and antibodies against CD19, CD20, CD22 or CD40 for the prevention or treatment of cancer. |
US20020165178A1 (en) | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
US20020198165A1 (en) | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
US20020091097A1 (en) | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
US6943240B2 (en) | 2000-09-15 | 2005-09-13 | Coley Pharmaceuticals Gmbh | Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist |
AU9475001A (en) | 2000-09-26 | 2002-04-08 | Hybridon Inc | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
CA2425358C (en) | 2000-10-18 | 2012-08-21 | Glaxosmithkline Biologicals S.A. | A vaccine composition comprising qs21, mpl, a cpg oligonucleotide and a cancer antigen |
ES2307568T3 (en) | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | CPG TYPE NUCLEIC ACIDS AND SAME USE METHODS. |
US20030055014A1 (en) * | 2000-12-14 | 2003-03-20 | Bratzler Robert L. | Inhibition of angiogenesis by nucleic acids |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
US7176296B2 (en) * | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US20040132677A1 (en) | 2001-06-21 | 2004-07-08 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same-IV |
DK2423335T3 (en) | 2001-06-21 | 2014-08-18 | Dynavax Tech Corp | CHEMICAL IMMUNAL MODULATOR RELATIONS AND PROCEDURES FOR USE THEREOF |
US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
US20030003970A1 (en) * | 2001-06-28 | 2003-01-02 | Alan Johnson | Portable communications device |
US20030148316A1 (en) | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
US20030067902A1 (en) * | 2001-09-21 | 2003-04-10 | Skeba Kirk W. | Method for providing multiple certified radio modules with a baseband |
EP1451581A4 (en) | 2001-10-05 | 2006-01-11 | Coley Pharm Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
AU2002360278A1 (en) | 2001-10-12 | 2003-11-11 | Coley Pharmaceutical Gmbh | Methods and products for enhancing immune responses using imidazoquinoline compounds |
RU2185819C1 (en) * | 2001-10-18 | 2002-07-27 | Дорофеенко Алла Ивановна | Agent showing antitumor effect |
US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US20030232443A1 (en) | 2002-06-18 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of centromere protein B expression |
NZ573064A (en) | 2002-04-04 | 2011-02-25 | Coley Pharm Gmbh | Immunostimulatory G,U-containing oligoribonucleotides |
HUE037352T2 (en) | 2002-04-05 | 2018-08-28 | Roche Innovation Ct Copenhagen As | Oligomeric compounds for the modulation of hif-1alpha expression |
WO2003103586A2 (en) * | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
WO2004007743A2 (en) | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
CN1468957A (en) | 2002-07-19 | 2004-01-21 | 中国人民解放军第二军医大学 | Plasmid used as human therapeutic vaccine adjuvant |
AU2003278845A1 (en) | 2002-09-19 | 2004-04-08 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
WO2004053104A2 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
US7625872B2 (en) | 2002-12-23 | 2009-12-01 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
US7851453B2 (en) * | 2003-01-16 | 2010-12-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
CA2521050A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
EP1631687A2 (en) | 2003-04-22 | 2006-03-08 | Coley Pharmaceutical GmbH | Methods and products for identification and assessment of tlr ligands |
CA2528597C (en) * | 2003-06-11 | 2014-08-05 | Hybridon, Inc. | Stabilized immunomodulatory oligonucleotides |
WO2005007672A2 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (tlr) antagonists |
EP1663316A2 (en) | 2003-09-25 | 2006-06-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid lipophilic conjugates |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
CN101094594B (en) | 2003-12-08 | 2012-08-15 | 海布里顿公司 | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
EP1720568A2 (en) | 2004-02-19 | 2006-11-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
US20060019916A1 (en) * | 2004-04-02 | 2006-01-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing IL-10 responses |
CA2567789A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
US7427405B2 (en) * | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
RU2007101039A (en) | 2004-06-15 | 2008-07-20 | Айдера Фармасьютикалз | IMMUNITIES MULATING OLIGONUCLEOTIDE MULTIMERS |
US20060287263A1 (en) | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing antigen-specific immune responses |
EP1776105A2 (en) * | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
AU2006216493A1 (en) * | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Gmbh | Immunostimulatory oligonucleotides |
RS20070422A (en) | 2005-04-08 | 2009-01-22 | Sanofi-Aventis U.S. Llc., | Methods for treating infectious disease exacerbated asthma |
AU2006241149A1 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
BRPI0612408A2 (en) * | 2005-07-07 | 2010-11-03 | Pfizer | cancer therapy in combination with anti-ctla-4 antibody and synthetic oligodeoxynucleotide containing cpg motif |
US20090214578A1 (en) | 2005-09-16 | 2009-08-27 | Coley Pharmaceutical Gmbh | Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone |
EP1924692A2 (en) | 2005-09-16 | 2008-05-28 | Coley Pharmaceutical GmbH | Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification |
CN102517292B (en) | 2005-11-25 | 2014-12-24 | 佐蒂斯比利时股份有限公司 | Immunostimulatory oligoribonucleotides |
ES2526879T3 (en) * | 2006-02-15 | 2015-01-16 | Adiutide Pharmaceuticals Gmbh | Compositions and procedures for oligonucleotide formulations |
US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
MX2009003398A (en) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
BRPI0719445A2 (en) | 2006-09-27 | 2013-12-10 | Coley Pharm Group Inc | COMPOSITIONS OF TLR AND ANTIVIAL LIGANDS. |
CA2667297A1 (en) | 2006-10-26 | 2008-11-20 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
US20090142362A1 (en) | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
AU2008252577A1 (en) | 2007-05-17 | 2008-11-27 | Coley Pharmaceutical Gmbh | Class A oligonucleotides with immunostimulatory potency |
-
2004
- 2004-10-29 US US10/978,283 patent/US8188254B2/en not_active Expired - Fee Related
- 2004-10-29 UA UAA200605917A patent/UA88457C2/en unknown
- 2004-10-29 EP EP04810173A patent/EP1678303A2/en not_active Withdrawn
- 2004-10-29 ZA ZA200602352A patent/ZA200602352B/en unknown
- 2004-10-29 AU AU2004285561A patent/AU2004285561C1/en not_active Ceased
- 2004-10-29 GE GEAP20049419A patent/GEP20094767B/en unknown
- 2004-10-29 KR KR1020067008222A patent/KR101107818B1/en not_active IP Right Cessation
- 2004-10-29 OA OA1200600139A patent/OA13278A/en unknown
- 2004-10-29 EP EP06112187A patent/EP1728863A3/en not_active Withdrawn
- 2004-10-29 BR BRPI0416079-7A patent/BRPI0416079A/en not_active IP Right Cessation
- 2004-10-29 JP JP2006538383A patent/JP2007509983A/en active Pending
- 2004-10-29 AP AP2006003611A patent/AP2006003611A0/en unknown
- 2004-10-29 SG SG200603240A patent/SG122973A1/en unknown
- 2004-10-29 SG SG200604397A patent/SG123799A1/en unknown
- 2004-10-29 NZ NZ546475A patent/NZ546475A/en unknown
- 2004-10-29 NZ NZ546275A patent/NZ546275A/en unknown
- 2004-10-29 EA EA200600865A patent/EA008741B1/en not_active IP Right Cessation
- 2004-10-29 WO PCT/US2004/036240 patent/WO2005042018A2/en active Application Filing
- 2004-10-29 CA CA002540949A patent/CA2540949A1/en not_active Abandoned
- 2004-10-29 CN CNA2004800320184A patent/CN101454451A/en active Pending
-
2006
- 2006-03-20 IL IL174428A patent/IL174428A0/en unknown
- 2006-04-10 AU AU2006201495A patent/AU2006201495A1/en not_active Abandoned
- 2006-04-21 ZA ZA200603212A patent/ZA200603212B/en unknown
- 2006-04-26 NO NO20061857A patent/NO20061857L/en not_active Application Discontinuation
- 2006-04-26 IL IL175215A patent/IL175215A0/en unknown
- 2006-04-28 TN TNP2006000123A patent/TNSN06123A1/en unknown
- 2006-05-29 MA MA29062A patent/MA28182A1/en unknown
- 2006-05-29 CR CR8423A patent/CR8423A/en not_active Application Discontinuation
- 2006-05-29 EC EC2006006589A patent/ECSP066589A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003015711A2 (en) * | 2001-08-17 | 2003-02-27 | Coley Pharmaceutical Group, Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
WO2004016805A2 (en) * | 2002-08-19 | 2004-02-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
WO2004039829A2 (en) * | 2002-10-29 | 2004-05-13 | Coley Pharmaceutical Group, Ltd. | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9404126B2 (en) | 2006-06-12 | 2016-08-02 | Kuros Biosciences Ag | Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages |
US9382545B2 (en) | 2006-09-27 | 2016-07-05 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US9328346B2 (en) | 2010-11-12 | 2016-05-03 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005042018A3 (en) | C-class oligonucleotide analogs with enhanced immunostimulatory potency | |
GB0025577D0 (en) | Vaccine | |
MY165643A (en) | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | |
WO2000061151A3 (en) | Oligodeoxynucleotide and its use to induce an immune response | |
WO2009022215A8 (en) | Combination motif immune stimulatory oligonucleotides with improved activity | |
IL145982A0 (en) | Vaccines | |
MA28149A1 (en) | VACCINE COMPOSITIONS COMPRISING AN INTERLEUKIN 18 AND A SAPONINE-LIKE ADJUVANT SYSTEM | |
DK1104306T3 (en) | Preparations of CpG and Saponin Adjuvants and Methods for Using Them | |
AU4358801A (en) | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences | |
WO2004071426A3 (en) | Compounds for the treatment of viral infection | |
GB0123580D0 (en) | Vaccine | |
HUP0402259A2 (en) | Vaccines | |
WO2009060281A3 (en) | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | |
WO2002087494A3 (en) | Novel vaccine | |
AU2002249852A1 (en) | Enhancement of immune response to vaccine by interferon alpha | |
WO2003039592A3 (en) | Cellular vaccines comprising adjuvants | |
MY127452A (en) | Vaccines. | |
CA2533434A1 (en) | Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof | |
MD2053C2 (en) | Remedy with interferon inducing action | |
WO2004013166A3 (en) | S. aureus antigene | |
EP1950296A3 (en) | Oligodeoxynucleotide and its use to induce an immune response | |
UA67251A (en) | Strain paramixovirus-3 bovis "zksm" for the preparation of vaccines and diagnosticums | |
UA67250A (en) | Strain bovinae herpesvirus-1 "moldavian" for the preparation of vaccines and diagnosticums |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480032018.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 174428 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004285561 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/02352 Country of ref document: ZA Ref document number: 200602352 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2540949 Country of ref document: CA Ref document number: 546275 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004810173 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006500712 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2004285561 Country of ref document: AU Date of ref document: 20041029 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004285561 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 175215 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006538383 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067008222 Country of ref document: KR Ref document number: PA/a/2006/004891 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: AP/P/2006/003611 Country of ref document: AP |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2006000227 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1367/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 06050574 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200600865 Country of ref document: EA Ref document number: CR2006-008423 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9419 Country of ref document: GE Ref document number: 20060202 Country of ref document: UZ Ref document number: 1200600860 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004810173 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067008222 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0416079 Country of ref document: BR |